Deal overview
| Target | LONGBOARD PHARMACEUTICALS INC |
|---|---|
| Bidder | H LUNDBECK A/S |
| Price | £90.00 Full version or £25.00 Light version |
| Publication Date | Oct 14, 2024 |
| Abstract | On 14 October 2024, the quoted Danish biopharmaceutical company H. Lundbeck A/S ("Lundbeck") announced a cash offer for the US-quoted biopharmaceutical company Longboard Pharmaceuticals, Inc ("Longboard"). Lundbeck would pay US$ 60 per Longboard share. The terms implied an equity value of US$ 2.6 billion for 100% of the company's share capital. The board of directors of both ... |
| Number of pages (Full version) | 9 |
| Number of pages (Light version) | 2 |
| Format | Adobe Acrobat (Download Acrobat Reader) |
| Free Sample | Click Here to Download |
Purchase this report
Buy and download this report in a fast a safe way using our secure payment system. We accept all major credit cards.
©2025 M&A Monitor Limited
